Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2007 2
2008 1
2009 3
2010 9
2011 5
2012 3
2013 2
2014 3
2015 6
2016 2
2017 3
2018 4
2019 1
2020 1
2021 1
2022 1
2023 1
2024 1
2025 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

46 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for davide pastorelli
Search for Davide Passarelli instead (1 results)
Nutritional Intervention for the Elderly during Chemotherapy: A Systematic Review.
Vella R, Pizzocaro E, Bannone E, Gualtieri P, Frank G, Giardino A, Frigerio I, Pastorelli D, Gruttadauria S, Mazzali G, di Renzo L, Butturini G. Vella R, et al. Among authors: pastorelli d. Cancers (Basel). 2024 Aug 9;16(16):2809. doi: 10.3390/cancers16162809. Cancers (Basel). 2024. PMID: 39199582 Free PMC article. Review.
Second-line therapy for refractory renal-cell carcinoma.
Zustovich F, Lombardi G, Nicoletto O, Pastorelli D. Zustovich F, et al. Among authors: pastorelli d. Crit Rev Oncol Hematol. 2012 Jul;83(1):112-22. doi: 10.1016/j.critrevonc.2011.08.008. Epub 2011 Sep 22. Crit Rev Oncol Hematol. 2012. PMID: 21944739 Review.
Real-World Treatment with Nivolumab or Cabozantinib for Metastatic Renal Cell Carcinoma (mRCC) in the Veneto Region of Italy: Results of AMOUR Study.
Maruzzo M, Pierantoni F, Bortolami A, Palleschi D, Zivi A, Nicodemo M, Sartori D, De Vivo R, Zustovich F, Bimbatti D, Pastorelli D, Vultaggio GD, Soraru' M, Ballestrin M, Modonesi C, Randisi P, Barile C, Perri G, Basso U, Zagonel V. Maruzzo M, et al. Among authors: pastorelli d. Target Oncol. 2022 Jul;17(4):467-474. doi: 10.1007/s11523-022-00892-z. Epub 2022 Jun 25. Target Oncol. 2022. PMID: 35751733 Free PMC article.
Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study.
Chau I, Park JO, Ryoo BY, Yen CJ, Poon R, Pastorelli D, Blanc JF, Kudo M, Pfiffer T, Hatano E, Chung HC, Kopeckova K, Phelip JM, Brandi G, Ohkawa S, Li CP, Okusaka T, Hsu Y, Abada PB, Zhu AX. Chau I, et al. Among authors: pastorelli d. Br J Cancer. 2018 Jul;119(1):19-26. doi: 10.1038/s41416-018-0103-0. Epub 2018 May 29. Br J Cancer. 2018. PMID: 29808014 Free PMC article. Clinical Trial.
Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study.
Rimassa L, Assenat E, Peck-Radosavljevic M, Pracht M, Zagonel V, Mathurin P, Rota Caremoli E, Porta C, Daniele B, Bolondi L, Mazzaferro V, Harris W, Damjanov N, Pastorelli D, Reig M, Knox J, Negri F, Trojan J, López López C, Personeni N, Decaens T, Dupuy M, Sieghart W, Abbadessa G, Schwartz B, Lamar M, Goldberg T, Shuster D, Santoro A, Bruix J. Rimassa L, et al. Among authors: pastorelli d. Lancet Oncol. 2018 May;19(5):682-693. doi: 10.1016/S1470-2045(18)30146-3. Epub 2018 Apr 3. Lancet Oncol. 2018. PMID: 29625879 Clinical Trial.
46 results